• 1
    Appignani BA, Bhadelia RA, Blacklow SC, Wang AK, Roland SF, Freeman RB Jr (1996) Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. AJR Am J Roentgenol 166: 683688.
  • 2
    Atkison PR, Joubert GI, Guiraudon C., Armstrong R., Wall W., Asfar S., Grant D. (1997) Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. Transplantation 64: 773775.
  • 3
    Burkhalter EL, Starzl TE, Thiel DH van (1994) Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. J Hepatol 21: 572577.
  • 4
    Emre S., Abouljoud M., For the OLN 452 Study Group (1999) Conversion to Neoral® provides effective rescue therapy for liver transplant patients intolerant of Progral®. An interim analysis of a prospective study (abstract). Transplantation 67: S32.
  • 5
    Emre S., Kelly D., O'Rourke M., Sheiner P., Guy S., Schluger LK, Schwartz M., Miller C. (1995) First year of tacrolimus: have we learned to use it safely? (abstract) Hepatology 22: 140A.
  • 6
    Fisher A., Schwartz M., Mor E., Sheiner P., Emre S., Guy S., Miller C. (1994) Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. Transplant Proc 26: 31063107.
  • 7
    Fisher A., Mor E., Hytiroglou P., Emre S., Boccagni P., Sheiner P., Schwartz M., Thung S., Miller C. (1995) FK506 hepatoxicity in liver allograft recipients. Transplantation 59: 16311632.
  • 8
    Fung JJ, Starzl TE (1995) FK506 in solid organ transplantation. Ther Drug Monit 17: 592595.
  • 9
    Hytiroglou P., Lee R., Sharma K., Theise ND, Schwartz M., Miller C., Thung SN (1993) FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. Transplantation 56: 13891391.
  • 10
    Jindal RM, Popescu I., Schwartz ME, Emre S., Boccagni P., Miller CM (1994) Diabetogenicity of FK 506 versus cyclosporine in liver transplant recipients. Transplantation 58: 370372.
  • 11
    Jonas S., Kling N., Bechstein WO, Blumhardt G., Lohmann R., Lobeek H., Neuhaus P. (1995) Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. Clin Transplant 9: 406.
  • 12
    Kershner RP, Fitzsimmons WE (1996) Relationship of FK 506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62: 920926.
  • 13
    Margarit C., Rimola A., Gonzalez-Pinto I., Cuervas-Mons V., Edo A., Andreu H., Moreno-Gonzalez E., Calleja JL (1998) Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transpl Int 11 [Suppl 1]: S260S266.
  • 14
    Mor E., Schwersenz A., Sheiner PA, Emre S., Schwartz ME, Miller CM (1994) Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. Transplantation 57: 11301131.
  • 15
    Mor E., Sheiner PA, Schwartz ME, Emre S., Guy S., Miller CM (1994) Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. Transplantation 58: 380382.
  • 16
    Neuhaus P., Blumhardt G., Bechstein WO, Platz KP, Jonas S., Mueller AR, Langrehr JM, Lohmann R., Schatten-froh N., Knoop M., Keck H., Lemmens P., Raakow R., Lüsebrink R., Slama KJ, Lobeck H., Hopf U. (1995) Comparison of FK 506- and cyclosporinebased immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation 59: 3140.
  • 17
    Platz KP, Mueller AR, Blumhardt G., Bachmann S., Bechstein WO, Kahl A., Neuhaus P. (1994) Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK 506. Transplantation 58: 170178.
  • 18
    Platz KP, Mueller AR, Jonas S., Blumhardt G., Bechstein WO, Lobeck H., Neuhaus HL (1995) Toxicity versus rejection - or why conversions between cyclosporine A and FK 506 were performed after liver transplantation. Clin Transplant 9: 146154.
  • 19
    Pratschke J., Neuhaus R., Tullius SG, Haller GW, Jonas S., Steinmueller T., Bechstein WO, Neuhaus P. (1997) Treatment of cyclosporine-related adverse effects by conversion to tacroli-mus after liver transplantation. Transplantation 64: 938940.
  • 20
    Sher LS, Cosenza CA, Michel J., Makowka L., Miller CM, Schwartz ME, Busuttil R., McDiarmid S., Burdick JF, Klein AS, Esquivel C., Klintmalm G., Levy M., Roberts JP, Lake JR, Kalayoglu M., D'Alessandro AM, Gordon RD, Stieber AC, Shaw BW Jr, Thistleth-waite JR, Whittington P., Wiesner RH, Porayko M., Bynon JS, Eckhoff DE, Freeman RB, Rohrer RJ, Lewis WD, Marsh JW, Peters M., Powelson J., Cosimi AB (1997) Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation. A report of the U. S. Multicenter Liver Study Group. Transplantation 64: 258263.
  • 21
    Steinmüller TM, Gräf KJ, Schleicher J., Leder K., Bechstein WO, Mueller AR, Dette K., Schulz E., Neuhaus P. (1994) The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 58: 669674.
  • 22
    Tabasco-Minguillan J., Mieles L., Carroll P., Gavaler J., Thiel DH van, Starzl TE (1993) Insulin requirements after liver transplantation and FK-506 immunosuppression. Transplantation 56: 862867.